Log In
Print
BCIQ
Print
Print this Print this
 

ALX-0751

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobody against an undisclosed target
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today